Loading
Latest filing published 16 Aug 2022 for Xenon Pharmaceuticals Inc., €60k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
James R. Empfield, listed as senior executive, appears in our data through filings on Xenon Pharmaceuticals Inc. shares, published by SEC (Form 4). Between 4 March 2022 and 12 August 2022, the trades on record add up to 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 16 August 2022 came the latest disclosure, an option exercise for €60k in Xenon Pharmaceuticals Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations